$2.27
0.00%
NYSE, Thu, Jun 05 2025
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

ACELYRIN Stock price

$2.27
-0.27 10.63% 1M
-1.94 46.08% 6M
-0.87 27.71% YTD
-1.88 45.30% 1Y
-15.73 87.39% 5Y
-15.73 87.39% 10Y
-15.73 87.39% 20Y
NYSE, Closing price Thu, Jun 05 2025
+0.00 0.00%
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

Key metrics

Market capitalization $229.16m
Enterprise Value $-181.43m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.63
P/B ratio (TTM) P/B ratio 0.56
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-293.34m
Free Cash Flow (TTM) Free Cash Flow $-286.77m
Cash position $410.59m
EPS (TTM) EPS $-2.66
Short interest 3.85%
Show more

Is ACELYRIN a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

ACELYRIN Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a ACELYRIN forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a ACELYRIN forecast:

Buy
100%

Financial data from ACELYRIN

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 60 60
24% 24%
-
- Research and Development Expense 208 208
16% 16%
-
-293 -293
10% 10%
-
- Depreciation and Amortization 0.48 0.48
182% 182%
-
EBIT (Operating Income) EBIT -293 -293
10% 10%
-
Net Profit -269 -269
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about ACELYRIN directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACELYRIN Stock News

Neutral
GlobeNewsWire
about one month ago
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis I...
Neutral
GlobeNewsWire
about one month ago
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today
Neutral
GlobeNewsWire
about one month ago
Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reiterated its confidence that th...
More ACELYRIN News

Company Profile

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Head office United States
CEO Mina Kim
Employees 93
Founded 2020
Website www.acelyrin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today